|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
CDER?s Division of Post-Marketing Evaluation for Quality Assessment
The new Division of Post Marketing Evaluation in the Office of New Drug Quality Assessment has implemented an improved system for managing the submission and review processes for post approval chemistry, manufacturing, and controls change supplements.
Advertisement
Articles in this issue
about 20 years ago
Analytical Instrument Qualificationabout 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?about 20 years ago
Team Effortabout 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedabout 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionabout 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressabout 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefabout 20 years ago
New Climateabout 20 years ago
2006: A Regulatory OdysseyAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
The Silent Crisis: Can The Demise of Chromatography Teaching in Universities Be Reversed?
2
Conference Talk: Current Trends in Separation Science
3
GC-MS Reveals Regional Flavor and Aroma Shifts in Oranges
4
LC-MS Reveals Food-Linked Stress Proteins
5